Lauren E. Higdon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lauren E. Higdon has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan S. Maltzman
Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
9 shared publications - Purvesh Khatri
Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA
3 shared publications - Alice E. Wiedeman
Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA
2 shared publications Brandon Ginley
Department of Pathology and Anatomical Sciences, University at Buffalo–The State University of New York, Buffalo, New York
2 shared publicationsBriana Santo
Department of Pathology and Anatomical Sciences, University at Buffalo–The State University of New York, Buffalo, New York
2 shared publicationsCatherine Li
Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California
2 shared publications
Latest Publications
- Open Access
FOXP-stabilization of the Il2ra super-enhancer structure augments Treg fitness
Gene expression in regulatory T cells (Tregs) is context-dependent and maintains peripheral immune homeostasis. FOXP3 is lineage defining but not sufficient for Treg function or persistence. To define the cell-intrinsic roles of the FOXP3 paralogs FOXP1 and FOXP4, we generated and studied mice with Treg-specific deletion of Foxp1 and/or Foxp4 . FOXP1 and FOXP4 are required to maintain the peripheral Treg pool through enhancing Il2ra transcription, thereby promoting sustained high-level expression of IL-2Rα and thus of the high-affinity IL-2Rαβγ complex. Integrating RNA-seq and ATAC-seq with previously published ChIA-PET and publicly available data, we propose a model of Il2ra transcriptional regulation in which in which FOXP1 and FOXP4 anchor chromatin looping of the Il2ra locus in mature Tregs, augment super-enhancer activity, and drive sustained CD25 expression. Our results reveal a unique role of FOXP1, and to a lesser extent FOXP4, in controlling Treg homeostasis. One Sentence Summary: FOXP1 and FOXP4 regulate chromatin architecture at the Il2ra locus, promoting sustained CD25 expression and maintaining the peripheral Treg pool.
Open AccessFOXP-stabilization of the Il2ra super-enhancer structure augments Treg fitness
Gene expression in regulatory T cells (Tregs) is context-dependent and maintains peripheral immune homeostasis. FOXP3 is lineage defining but not sufficient for Treg function or persistence. To define the cell-intrinsic roles of the FOXP3 paralogs FOXP1 and FOXP4, we generated and studied mice with Treg-specific deletion of Foxp1 and/or Foxp4 . FOXP1 and FOXP4 are required to maintain the peripheral Treg pool through enhancing Il2ra transcription, thereby promoting sustained high-level expression of IL-2Rα and thus of the high-affinity IL-2Rαβγ complex. Integrating RNA-seq and ATAC-seq with previously published ChIA-PET and publicly available data, we propose a model of Il2ra transcriptional regulation in which in which FOXP1 and FOXP4 anchor chromatin looping of the Il2ra locus in mature Tregs, augment super-enhancer activity, and drive sustained CD25 expression. Our results reveal a unique role of FOXP1, and to a lesser extent FOXP4, in controlling Treg homeostasis. One Sentence Summary: FOXP1 and FOXP4 regulate chromatin architecture at the Il2ra locus, promoting sustained CD25 expression and maintaining the peripheral Treg pool.
- Open Access
Baseline Serum Metabolites as Predictors of Teplizumab Response in Individuals with Type 1 Diabetes
Aims/hypothesis: Immunotherapies such as Teplizumab can preserve residual beta cell function in individuals with newly diagnosed type 1 diabetes (T1D), but treatment response is variable. Currently, no biomarker exists to identify individuals most likely to benefit from immunotherapy. We believe that baseline serum metabolomic profiles can distinguish individuals who respond to treatment from nonresponders and predict therapeutic response. Methods: Baseline serum samples from 41 individuals newly diagnosed with T1D enrolled in the AbATE trial ( NCT00129259 ) were analyzed to identify metabolic predictors of response to Teplizumab therapy in the AbATE trial. Responders to Teplizumab, as per study protocol, were defined as individuals who exhibited less than a 40% decline in baseline C-peptide levels at 2 years after start of treatment. We analyzed baseline serum samples using a semi-targeted metabolomics approach via liquid chromatography–high-resolution tandem mass spectrometry. Metabolites that were significantly different between responders and nonresponders were identified (P < 0.05), and the significant metabolites were used to train a supervised Random Forest model to predict treatment response. Model performance was evaluated using a 70/30 training/testing split, 5-fold cross-validation, bootstrap resampling (1,000 iterations), and permutation testing (1,000 permutations). Results: We identified 15 significantly different metabolites at baseline between responders and nonresponders (P < 0.05). These metabolites included amino acids and their derivatives, tricarboxylic acid (TCA) cycle intermediates, and microbially derived metabolites. At baseline, responders exhibited higher levels of TCA cycle metabolites, amino acid derivatives, and microbial metabolites, whereas nonresponders showed elevated levels of glutamate and acylcarnitines. The Random Forest classifier achieved an accuracy of 0.769 and an area under the receiver operating characteristic curve (AUC) of 0.881 in the test dataset. Cross-validation yielded a mean AUC of 0.856 (SD 0.156; 95% CI 0.719–0.992). Bootstrap analysis produced a test AUC 95% CI of 0.619–1.000, and permutation testing confirmed significance (p = 0.012). Conclusions/interpretation: Baseline serum metabolomic signatures can predict responders to Teplizumab with high accuracy. This could potentially be applicable when considering other immunotherapies in preventative efforts in T1D. Trial registration: ClinicalTrials.gov NCT00129259 . Research in Context: What is already known about this subject?: Teplizumab can delay beta cell decline in individuals with newly diagnosed T1D, but treatment response varies. No validated biomarkers currently exist to predict which individuals will respond to immunotherapy. Metabolomic profiling has shown potential for identifying metabolic signatures associated with disease progression and immune activity in T1D. What is the key question?: Can baseline serum metabolomic profiles predict which individuals with newly diagnosed T1D will respond to Teplizumab therapy? What are the new findings?: Fifteen baseline metabolites differed significantly between responders and nonresponders, including amino acid derivatives, tricarboxylic acid cycle intermediates, and microbially derived metabolites. Responders exhibited metabolic signatures consistent with preserved beta cell function and enhanced mitochondrial and immune-regulatory activity. A Random Forest model developed using these metabolites accurately predicted treatment response (AUC 0.881), demonstrating strong predictive potential. How might this impact on clinical practice in the foreseeable future?: Baseline metabolomic profiling could support personalized treatment strategies by identifying individuals most likely to benefit from treatment with Teplizumab or other immunotherapies.
Open AccessBaseline Serum Metabolites as Predictors of Teplizumab Response in Individuals with Type 1 Diabetes
Aims/hypothesis: Immunotherapies such as Teplizumab can preserve residual beta cell function in individuals with newly diagnosed type 1 diabetes (T1D), but treatment response is variable. Currently, no biomarker exists to identify individuals most likely to benefit from immunotherapy. We believe that baseline serum metabolomic profiles can distinguish individuals who respond to treatment from nonresponders and predict therapeutic response. Methods: Baseline serum samples from 41 individuals newly diagnosed with T1D enrolled in the AbATE trial ( NCT00129259 ) were analyzed to identify metabolic predictors of response to Teplizumab therapy in the AbATE trial. Responders to Teplizumab, as per study protocol, were defined as individuals who exhibited less than a 40% decline in baseline C-peptide levels at 2 years after start of treatment. We analyzed baseline serum samples using a semi-targeted metabolomics approach via liquid chromatography–high-resolution tandem mass spectrometry. Metabolites that were significantly different between responders and nonresponders were identified (P < 0.05), and the significant metabolites were used to train a supervised Random Forest model to predict treatment response. Model performance was evaluated using a 70/30 training/testing split, 5-fold cross-validation, bootstrap resampling (1,000 iterations), and permutation testing (1,000 permutations). Results: We identified 15 significantly different metabolites at baseline between responders and nonresponders (P < 0.05). These metabolites included amino acids and their derivatives, tricarboxylic acid (TCA) cycle intermediates, and microbially derived metabolites. At baseline, responders exhibited higher levels of TCA cycle metabolites, amino acid derivatives, and microbial metabolites, whereas nonresponders showed elevated levels of glutamate and acylcarnitines. The Random Forest classifier achieved an accuracy of 0.769 and an area under the receiver operating characteristic curve (AUC) of 0.881 in the test dataset. Cross-validation yielded a mean AUC of 0.856 (SD 0.156; 95% CI 0.719–0.992). Bootstrap analysis produced a test AUC 95% CI of 0.619–1.000, and permutation testing confirmed significance (p = 0.012). Conclusions/interpretation: Baseline serum metabolomic signatures can predict responders to Teplizumab with high accuracy. This could potentially be applicable when considering other immunotherapies in preventative efforts in T1D. Trial registration: ClinicalTrials.gov NCT00129259 . Research in Context: What is already known about this subject?: Teplizumab can delay beta cell decline in individuals with newly diagnosed T1D, but treatment response varies. No validated biomarkers currently exist to predict which individuals will respond to immunotherapy. Metabolomic profiling has shown potential for identifying metabolic signatures associated with disease progression and immune activity in T1D. What is the key question?: Can baseline serum metabolomic profiles predict which individuals with newly diagnosed T1D will respond to Teplizumab therapy? What are the new findings?: Fifteen baseline metabolites differed significantly between responders and nonresponders, including amino acid derivatives, tricarboxylic acid cycle intermediates, and microbially derived metabolites. Responders exhibited metabolic signatures consistent with preserved beta cell function and enhanced mitochondrial and immune-regulatory activity. A Random Forest model developed using these metabolites accurately predicted treatment response (AUC 0.881), demonstrating strong predictive potential. How might this impact on clinical practice in the foreseeable future?: Baseline metabolomic profiling could support personalized treatment strategies by identifying individuals most likely to benefit from treatment with Teplizumab or other immunotherapies.
- Open Access
- 1 January 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 214 (1) , 12-22
Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes
The CD2-depleting drug alefacept (LFA3-Ig) preserved beta cell function in new-onset type 1 diabetes (T1D) patients. The most promising biomarkers of response were late expansion of exhausted CD8 T cells and rare baseline inflammatory islet-reactive CD4 T cells, neither of which can be used to measure responses to drug in the weeks after treatment. Thus, we investigated whether early changes in T cell immunophenotypes could serve as biomarkers of drug activity. We characterized T cell responses by flow cytometry and identified an exhausted-like population of CD2low CD4 effector memory T cells coexpressing TIGIT and PD1 that expanded by 11 wk after the start of treatment. This population was not entirely spared from alefacept-mediated depletion in vivo or in vitro but recovered through homeostatic proliferation of CD2low cells in vivo. Proliferation of TIGIT+PD1+ effector memory CD4 T cells increased with treatment, with a concomitant reduction of proinflammatory cytokine production. The persistent increase of TIGIT+PD1+ effector memory CD4 T cells was specific to alefacept treatment; 2 other T cell depleting therapies, teplizumab and anti-thymocyte globulin, induced only a transient increase in this CD4 population. Our data suggest that the expanding TIGIT+PD1+ effector memory CD4 T cell population represents a promising biomarker of early treatment effects of alefacept. The nondepleting effects on proliferation and cytokine production also suggest agonistic activity by this CD2 targeted therapy.
- 1 January 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 214 (1) , 12-22
Open AccessEarly expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes
The CD2-depleting drug alefacept (LFA3-Ig) preserved beta cell function in new-onset type 1 diabetes (T1D) patients. The most promising biomarkers of response were late expansion of exhausted CD8 T cells and rare baseline inflammatory islet-reactive CD4 T cells, neither of which can be used to measure responses to drug in the weeks after treatment. Thus, we investigated whether early changes in T cell immunophenotypes could serve as biomarkers of drug activity. We characterized T cell responses by flow cytometry and identified an exhausted-like population of CD2low CD4 effector memory T cells coexpressing TIGIT and PD1 that expanded by 11 wk after the start of treatment. This population was not entirely spared from alefacept-mediated depletion in vivo or in vitro but recovered through homeostatic proliferation of CD2low cells in vivo. Proliferation of TIGIT+PD1+ effector memory CD4 T cells increased with treatment, with a concomitant reduction of proinflammatory cytokine production. The persistent increase of TIGIT+PD1+ effector memory CD4 T cells was specific to alefacept treatment; 2 other T cell depleting therapies, teplizumab and anti-thymocyte globulin, induced only a transient increase in this CD4 population. Our data suggest that the expanding TIGIT+PD1+ effector memory CD4 T cell population represents a promising biomarker of early treatment effects of alefacept. The nondepleting effects on proliferation and cytokine production also suggest agonistic activity by this CD2 targeted therapy.
- Open Access
- 2 May 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 217 (2) , 119-132
Impact on in-depth immunophenotyping of delay to peripheral blood processing
Peripheral blood mononuclear cell (PBMC) immunophenotyping is crucial in tracking activation, disease state, and response to therapy in human subjects. Many studies require the shipping of blood from clinical sites to a laboratory for processing to PBMC, which can lead to delays that impact sample quality. We used an extensive cytometry by time-of-flight (CyTOF) immunophenotyping panel to analyze the impacts of delays to processing and distinct storage conditions on cell composition and quality of PBMC from seven adults across a range of ages, including two with rheumatoid arthritis. Two or more days of delay to processing resulted in extensive red blood cell contamination and increased variability of cell counts. While total memory and naïve B- and T-cell populations were maintained, 4-day delays reduced the frequencies of monocytes. Variation across all immune subsets increased with delays of up to 7 days in processing. Unbiased clustering analysis to define more granular subsets confirmed changes in PBMC composition, including decreases of classical and non-classical monocytes, basophils, plasmacytoid dendritic cells, and follicular helper T cells, with each subset impacted at a distinct time of delay. Expression of activation markers and chemokine receptors changed by Day 2, with differential impacts across subsets and markers. Our data support existing recommendations to process PBMC within 36 h of collection but provide guidance on appropriate immunophenotyping experiments with longer delays.
- 2 May 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 217 (2) , 119-132
Open AccessImpact on in-depth immunophenotyping of delay to peripheral blood processing
Peripheral blood mononuclear cell (PBMC) immunophenotyping is crucial in tracking activation, disease state, and response to therapy in human subjects. Many studies require the shipping of blood from clinical sites to a laboratory for processing to PBMC, which can lead to delays that impact sample quality. We used an extensive cytometry by time-of-flight (CyTOF) immunophenotyping panel to analyze the impacts of delays to processing and distinct storage conditions on cell composition and quality of PBMC from seven adults across a range of ages, including two with rheumatoid arthritis. Two or more days of delay to processing resulted in extensive red blood cell contamination and increased variability of cell counts. While total memory and naïve B- and T-cell populations were maintained, 4-day delays reduced the frequencies of monocytes. Variation across all immune subsets increased with delays of up to 7 days in processing. Unbiased clustering analysis to define more granular subsets confirmed changes in PBMC composition, including decreases of classical and non-classical monocytes, basophils, plasmacytoid dendritic cells, and follicular helper T cells, with each subset impacted at a distinct time of delay. Expression of activation markers and chemokine receptors changed by Day 2, with differential impacts across subsets and markers. Our data support existing recommendations to process PBMC within 36 h of collection but provide guidance on appropriate immunophenotyping experiments with longer delays.
- 29 December 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (12) , 2059-2076
Endothelial Cell-Specific Molecule-1 Inhibits Albuminuria in Diabetic Mice
Key Points: Circulating endothelial cell-specific molecule-1 (Esm-1) inversely correlates with diabetic kidney disease. Addition of Esm-1 in susceptible mice reduces albuminuria, and deletion of Esm-1 in resistant mice mildly worsens albuminuria. Esm-1 attenuates podocyte injury and select IFN signaling, highlighting innate immunity as a potential mechanism of kidney disease. Background: Diabetic kidney disease (DKD) is the most common cause of kidney failure in the world, and novel predictive biomarkers and molecular mechanisms of disease are needed. Endothelial cell-specific molecule-1 (Esm-1) is a secreted proteoglycan that attenuates inflammation. We previously identified that a glomerular deficiency of Esm-1 associates with more pronounced albuminuria and glomerular inflammation in DKD-susceptible relative to DKD-resistant mice, but its contribution to DKD remains unexplored. Methods: Using hydrodynamic tail-vein injection, we overexpress Esm-1 in DKD-susceptible DBA/2 mice and delete Esm-1 in DKD-resistant C57BL/6 mice to study the contribution of Esm-1 to DKD. We analyze clinical indices of DKD, leukocyte infiltration, podocytopenia, and extracellular matrix production. We also study transcriptomic changes to assess potential mechanisms of Esm-1 in glomeruli. Results: In DKD-susceptible mice, Esm-1 inversely correlates with albuminuria and glomerular leukocyte infiltration. We show that overexpression of Esm-1 reduces albuminuria and diabetes-induced podocyte injury, independent of changes in leukocyte infiltration. Using a complementary approach, we find that constitutive deletion of Esm-1 in DKD-resistant mice modestly increases the degree of diabetes-induced albuminuria versus wild-type controls. By glomerular RNAseq, we identify that Esm-1 attenuates expression of kidney disease–promoting and interferon (IFN)-related genes, including Ackr2 and Cxcl11. Conclusions: We demonstrate that, in DKD-susceptible mice, Esm-1 protects against diabetes-induced albuminuria and podocytopathy, possibly through select IFN signaling. Companion studies in patients with diabetes suggest a role of Esm-1 in human DKD.
- 29 December 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (12) , 2059-2076
Endothelial Cell-Specific Molecule-1 Inhibits Albuminuria in Diabetic Mice
Key Points: Circulating endothelial cell-specific molecule-1 (Esm-1) inversely correlates with diabetic kidney disease. Addition of Esm-1 in susceptible mice reduces albuminuria, and deletion of Esm-1 in resistant mice mildly worsens albuminuria. Esm-1 attenuates podocyte injury and select IFN signaling, highlighting innate immunity as a potential mechanism of kidney disease. Background: Diabetic kidney disease (DKD) is the most common cause of kidney failure in the world, and novel predictive biomarkers and molecular mechanisms of disease are needed. Endothelial cell-specific molecule-1 (Esm-1) is a secreted proteoglycan that attenuates inflammation. We previously identified that a glomerular deficiency of Esm-1 associates with more pronounced albuminuria and glomerular inflammation in DKD-susceptible relative to DKD-resistant mice, but its contribution to DKD remains unexplored. Methods: Using hydrodynamic tail-vein injection, we overexpress Esm-1 in DKD-susceptible DBA/2 mice and delete Esm-1 in DKD-resistant C57BL/6 mice to study the contribution of Esm-1 to DKD. We analyze clinical indices of DKD, leukocyte infiltration, podocytopenia, and extracellular matrix production. We also study transcriptomic changes to assess potential mechanisms of Esm-1 in glomeruli. Results: In DKD-susceptible mice, Esm-1 inversely correlates with albuminuria and glomerular leukocyte infiltration. We show that overexpression of Esm-1 reduces albuminuria and diabetes-induced podocyte injury, independent of changes in leukocyte infiltration. Using a complementary approach, we find that constitutive deletion of Esm-1 in DKD-resistant mice modestly increases the degree of diabetes-induced albuminuria versus wild-type controls. By glomerular RNAseq, we identify that Esm-1 attenuates expression of kidney disease–promoting and interferon (IFN)-related genes, including Ackr2 and Cxcl11. Conclusions: We demonstrate that, in DKD-susceptible mice, Esm-1 protects against diabetes-induced albuminuria and podocytopathy, possibly through select IFN signaling. Companion studies in patients with diabetes suggest a role of Esm-1 in human DKD.
- Open Access
Endothelial Cell-Specific Molecule-1 Inhibits Albuminuria in Diabetic Mice
Diabetic kidney disease (DKD) is the most common cause of kidney failure in the world, and novel predictive biomarkers and molecular mechanisms of disease are needed. Endothelial cell-specific molecule-1 (Esm-1) is a secreted proteoglycan that attenuates inflammation. We previously identified that a glomerular deficiency of Esm-1 associates with more pronounced albuminuria and glomerular inflammation in DKD-susceptible relative to DKD-resistant mice, but its contribution to DKD remains unexplored. In this study, we show that lower circulating Esm-1 predicts progressive stages of albuminuria in patients with diabetes. In DKD-susceptible mice, Esm-1 inversely correlates with albuminuria and glomerular leukocyte infiltration. Using hydrodynamic tail-vein injection, we show that over-expression of either mouse or human Esm-1 reduces diabetes-induced albuminuria relative to saline-injected controls independent of leukocyte infiltration. Using a complementary approach, we find that constitutive deletion of Esm-1 in DKD-resistant mice increases the degree of diabetes-induced albuminuria versus wild-type controls. Mechanistically, over-expression of Esm-1 attenuates diabetes-induced podocyte injury. By glomerular RNAseq, we identify that Esm-1 attenuates diabetes-induced up-regulation of interferon-stimulated genes, and Esm-1 inhibits expression of kidney disease-promoting and interferon-related genes, including Ackr2 and Cxcl11 . In conclusion, we demonstrate that Esm-1 protects against diabetes-induced albuminuria, and podocytopathy, possibly through select interferon signaling.
Open AccessEndothelial Cell-Specific Molecule-1 Inhibits Albuminuria in Diabetic Mice
Diabetic kidney disease (DKD) is the most common cause of kidney failure in the world, and novel predictive biomarkers and molecular mechanisms of disease are needed. Endothelial cell-specific molecule-1 (Esm-1) is a secreted proteoglycan that attenuates inflammation. We previously identified that a glomerular deficiency of Esm-1 associates with more pronounced albuminuria and glomerular inflammation in DKD-susceptible relative to DKD-resistant mice, but its contribution to DKD remains unexplored. In this study, we show that lower circulating Esm-1 predicts progressive stages of albuminuria in patients with diabetes. In DKD-susceptible mice, Esm-1 inversely correlates with albuminuria and glomerular leukocyte infiltration. Using hydrodynamic tail-vein injection, we show that over-expression of either mouse or human Esm-1 reduces diabetes-induced albuminuria relative to saline-injected controls independent of leukocyte infiltration. Using a complementary approach, we find that constitutive deletion of Esm-1 in DKD-resistant mice increases the degree of diabetes-induced albuminuria versus wild-type controls. Mechanistically, over-expression of Esm-1 attenuates diabetes-induced podocyte injury. By glomerular RNAseq, we identify that Esm-1 attenuates diabetes-induced up-regulation of interferon-stimulated genes, and Esm-1 inhibits expression of kidney disease-promoting and interferon-related genes, including Ackr2 and Cxcl11 . In conclusion, we demonstrate that Esm-1 protects against diabetes-induced albuminuria, and podocytopathy, possibly through select interferon signaling.
- Open Access
- 22 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (8) , 2086-2095
Functional Consequences of Memory Inflation after Solid Organ Transplantation
CMV is a major infectious complication following solid organ transplantation. Reactivation of CMV leads to memory inflation, a process in which CD8 T cells expand over time. Memory inflation is associated with specific changes in T cell function, including increased oligoclonality, decreased cytokine production, and terminal differentiation. To address whether memory inflation during the first year after transplantation in human subjects alters T cell differentiation and function, we employed single-cell–matched TCRαβ and targeted gene expression sequencing. Expanded T cell clones exhibited a terminally differentiated, immunosenescent, and polyfunctional phenotype whereas rare clones were less differentiated. Clonal expansion occurring between pre- and 3 mo posttransplant was accompanied by enhancement of polyfunctionality. In contrast, polyfunctionality and differentiation state were largely maintained between 3 and 12 mo posttransplant. Highly expanded clones had a higher degree of polyfunctionality than rare clones. Thus, CMV-responsive CD8 T cells differentiated during the pre- to posttransplant period then maintained their differentiation state and functional capacity despite posttransplant clonal expansion.
- 22 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (8) , 2086-2095
Open AccessFunctional Consequences of Memory Inflation after Solid Organ Transplantation
CMV is a major infectious complication following solid organ transplantation. Reactivation of CMV leads to memory inflation, a process in which CD8 T cells expand over time. Memory inflation is associated with specific changes in T cell function, including increased oligoclonality, decreased cytokine production, and terminal differentiation. To address whether memory inflation during the first year after transplantation in human subjects alters T cell differentiation and function, we employed single-cell–matched TCRαβ and targeted gene expression sequencing. Expanded T cell clones exhibited a terminally differentiated, immunosenescent, and polyfunctional phenotype whereas rare clones were less differentiated. Clonal expansion occurring between pre- and 3 mo posttransplant was accompanied by enhancement of polyfunctionality. In contrast, polyfunctionality and differentiation state were largely maintained between 3 and 12 mo posttransplant. Highly expanded clones had a higher degree of polyfunctionality than rare clones. Thus, CMV-responsive CD8 T cells differentiated during the pre- to posttransplant period then maintained their differentiation state and functional capacity despite posttransplant clonal expansion.
- Open Access
- 22 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (8) , 2077-2085
Evolution of Cytomegalovirus-Responsive T Cell Clonality following Solid Organ Transplantation
CMV infection is a significant complication after solid organ transplantation. We used single cell TCR αβ sequencing to determine how memory inflation impacts clonality and diversity of the CMV-responsive CD8 and CD4 T cell repertoire in the first year after transplantation in human subjects. We observed CD8 T cell inflation but no changes in clonal diversity, indicating homeostatic stability in clones. In contrast, the CD4 repertoire was diverse and stable over time, with no evidence of CMV-responsive CD4 T cell expansion. We identified shared CDR3 TCR motifs among patients but no public CMV-specific TCRs. Temporal changes in clonality in response to transplantation and in the absence of detectable viral reactivation suggest changes in the repertoire immediately after transplantation followed by an expansion with stable clonal competition that may mediate protection.
- 22 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (8) , 2077-2085
Open AccessEvolution of Cytomegalovirus-Responsive T Cell Clonality following Solid Organ Transplantation
CMV infection is a significant complication after solid organ transplantation. We used single cell TCR αβ sequencing to determine how memory inflation impacts clonality and diversity of the CMV-responsive CD8 and CD4 T cell repertoire in the first year after transplantation in human subjects. We observed CD8 T cell inflation but no changes in clonal diversity, indicating homeostatic stability in clones. In contrast, the CD4 repertoire was diverse and stable over time, with no evidence of CMV-responsive CD4 T cell expansion. We identified shared CDR3 TCR motifs among patients but no public CMV-specific TCRs. Temporal changes in clonality in response to transplantation and in the absence of detectable viral reactivation suggest changes in the repertoire immediately after transplantation followed by an expansion with stable clonal competition that may mediate protection.
- 1 March 2019
- Published by Elsevier in Journal of Immunological Methods
- Vol. 466, 17-23
Optimization of single-cell plate sorting for high throughput sequencing applications
- 1 March 2019
- Published by Elsevier in Journal of Immunological Methods
- Vol. 466, 17-23
Optimization of single-cell plate sorting for high throughput sequencing applications
- Open Access
- 15 February 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (5) , 1278-1287
Single cell immune profiling in transplantation research
- 15 February 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (5) , 1278-1287
Open AccessSingle cell immune profiling in transplantation research